Since the first reports describing the injection of recombinant adeno-associated viral (AAV) vectors in the murine eye, the advancement of the field has been enormous resulting in the correction of several animal models of retinal diseases. The recent development of ''pseudotyped'' AAV vectors with transduction characteristics that best fit the correction of specific retinal disease phenotypes and of sophisticated systems for tight regulation of gene expression expands on the potentiality of this delivery system for the eye.
Recombinant vectors based on AAV serotypes
Recombinant adeno-associated viral (AAV) vectors are promising tools for gene transfer applications (Monahan & Samulski, 2000) . They derive from a singlestranded DNA virus which is a non-human pathogen (Berns, 1996) . Eight different isolates have been described to date. Four (AAV1-4) have been isolated as contaminants of human adenoviral cultures and one from a human condylomatous lesion (AAV5) (BantelSchaal & zur Hausen, 1984 ). AAV6 appears as an artefact hybrid between AAV1 and 2 (Xiao et al., 1999) . Very recently, sequences from two novel serotypes (AAV7 and 8) have been isolated from rhesus monkey tissues and have been used to create recombinant vectors (Gao et al., 2002) .
The best characterized AAV vector, which is currently employed in a clinical trial for FIX deficiency, derives from AAV2 (Atchinson, Casto, & Hammon, 1965) . AAV2-mediated transduction appears safe and stable in various tissues of animal models although levels of gene transfer are often disappointing. One AAV production strategy, based on transient transfection of the different vector components in trans (Xiao, Li, & Samulski, 1998) , allows for the exchange of the surface proteins (capsid) between different serotypes. This results in hybrid vectors with the same genome encoding for the therapeutic gene (i.e. from AAV2) packaged in capsids from different AAV serotypes (namely AAV2/1-8) (Fig. 1) .
The use of vectors based on different AAV serotypes has mainly two advantages. Pre-existing immunity to one serotype may be circumvented using a different capsid. In addition, AAV ''pseudotype'' transduction characteristics, such as onset and intensity of gene expression as well as tissue tropism, depend on the capsid. In mice in vivo, AAV2/1 and 2/7 vectors transduce muscle very efficiently (Chao et al., 2000; Gao et al., 2002; Rabinowitz et al., 2002) , while AAV2/5 enters the airway from the apical side (Zabner et al., 2000) and AAV2/8 is the most efficient AAV vector for liverdirected gene transfer (Gao et al., 2002) (Fig. 1) . Therefore, the capsid influences the events leading to transduction, including vector entry in the target cell through binding to a specific receptor, intracellular trafficking, nuclear entry and DNA double strand synthesis .
AAV vectors in the retina
The eye is an attractive target for gene therapies (Bennett & Maguire, 2000) , being small, enclosed and immune privileged. In addition, a number of inherited diseases affecting the eye have known gene defects; there are well-characterized animal models for many of these conditions; and many of the diseases progress slowly, therefore allowing for timely delivery of a potential treatment. Retinal diseases amenable to gene therapies are generally characterized by neuronal degeneration (i.e. retinitis pigmentosa) or by ocular neovascularization (i.e. diabetic retinopathy and age-related macular degeneration). Gene-based strategies to arrest or revert retinal diseases are generally aiming at gene replacement/targeting or at releasing a soluble factor exerting a neurotrophic/anti-angiogenic effect. In the first case, gene transfer has to occur in the specific cell type where the defect is localized, in the latter any retinal or ocular cell type in the proximity of the lesion can be transduced and used as a factory for production of the secreted therapeutic protein (Fig. 2) . AAV vectors, mainly based on serotype 2, have been tested in the retina (Ali et al., 1996 (Ali et al., , 1998 Bennett, Duan, Engelhardt, & Maguire, 1997; Bennett et al., 1999; Dreyer, Vorwerk, Zurakowski, Simon, & Bennett, 1999; Flannery et al., 1997; Grant, Ponnazhagan, Wang, Srivastava, & Li, 1997; Sarra et al., 2002) . AAV2 vectors transduce the retina of various animal models efficiently and stably resulting in the successful correction of several forms of retinitis pigmentosa (Acland et al., 2001; Ali et al., 2000) and ocular neovascularization (Auricchio et al., in press; Bainbridge et al., 2002; Mori et al., 2002; Raisler, Berns, Grant, Beliaev, & Hauswirth, 2002) . It is worth mentioning that Sarra et al. (2001) showed that gene transfer in the rds mouse had no significant effect on photoreceptor cell loss despite the improvements in morphology and function (Ali et al., 2000) , suggesting that, at least in this case, successful gene therapy may depend upon intervention in early stages of disease and upon accurate control of transgene expression. Subretinal injections of AAV2 vectors in mice and non-human primates (NHP) result mainly in targeting of the retinal pigment epithelium (RPE) and photoreceptor layer (Ali et al., 1996; Bennett et al., 1999; Flannery et al., 1997) , while intravitreal administration allows preferential transduction of Muller and retinal ganglion cells (Ali et al., 1996 (Ali et al., , 1998 Auricchio et al., 2001; Dreyer et al., 1999; Flannery et al., 1997) .
The exchange of the capsid between different AAV serotypes results in modifications of their retinal transduction characteristics Rabinowitz et al., 2002; Yang et al., 2002) . Following AAV subretinal administration in mice, the AAV1 capsid fa- vours RPE transduction, while AAV5 allows more efficient gene transfer in photoreceptors and RPE than AAV2 (Fig. 3) . In addition, the vectorÕs capsid influences the onset of gene expression: AAV2/1-mediated expression starts more rapidly (24-48 h after vector administration) than AAV2 (two to four weeks) and AAV2/5 is intermediate (two weeks) between the two. Taking into account the slow kinetic of AAV2 expression in the eye when compared to other AAV serotypes, the latter may be preferable for the correction of retinal diseases in animal models where an immediate onset of gene expression is required. For instance, the rod photoreceptor degeneration present in the rd mouse (bearing a mutation in the phosphodiesterase b subunit) (Chang et al., 2002 ) is complete by three weeks after birth, requiring that gene replacement occurs in the photoreceptors immediately after birth in order to preserve the retinal architecture. The description of retinal transduction by vectors based on various AAV serotypes Rabinowitz et al., 2002; Yang et al., 2002) will certainly impact on the choice of the appropriate AAV to use in animal models. For instance, AAV pseudotypes may allow NHP cones transduction, which are normally spared by AAV2 gene transfer . In conclusion, once confirmed in the NHP retina, the knowledge of AAV serotypes transduction characteristics will prove crucial to extend retinal gene transfer to humans.
AAV-mediated secretion of therapeutic proteins in the eye
Intraocular injections of AAV2 encoding a neurotrophic (Green et al., 2001; McGee Sanftner, Abel, Hauswirth, & Flannery, 2001) or anti-angiogenic molecule (Auricchio et al., in press; Bainbridge et al., 2002; Mori et al., 2002; Raisler et al., 2002) results in detectable expression of the molecule exerting the appropriate biological activity in the eye. Interestingly, intravitreal or subretinal administration of the vector does not significantly impact on the levels of soluble protein measured in the vitreous space or anterior chamber (Fig. 4) (Auricchio et al., 2002) .
The retinal neovascularization of the mouse model of retinopathy of prematurity (ROP) (Smith et al., 1994) peaks between post-natal day 19 and 21 and then regresses. Testing an anti-angiogenic gene-based therapy in the ROP eye requires rapid onset of gene expression. We successfully treated the retinas of ROP mice with AAV2/1 vectors encoding three different anti-angiogenic molecules (Fig. 5) (Auricchio et al., in press) , confirming that vectors with an AAV1 capsid trigger a rapid onset of gene expression in the retina. Interestingly, similar results have been obtained in the same model using an AAV2 vector (with slow onset of gene expression in the adult murine retina), suggesting that the newborn hypoxic retina may offer the cellular environment suitable for rapid conversion of the AAV genome in a transcriptionally active form .
AAV-mediated pharmacological regulation of gene expression in the eye
Whether gene therapy is used to exogenously replace a mutated gene in the eye or to provide a soluble factor with therapeutic activity, one major hurdle to overcome is obtaining appropriate levels of gene expression. The cargo capacity of most gene therapy vectors, including AAV, limits the possibility to include large endogenous gene regulatory elements. For this reason, a number of gene expression systems that are inducible upon the administration of a small molecule drug have been devised (for a comprehensive review see (Clackson, 2000) ). These systems are generally based on two elements: an engineered transcription factor whose activity is controlled by a small molecule drug and a target gene whose expression is driven by the regulated transcription factor. Pharmacological regulation of gene expression is hampered by the risks of the drugÕs frequent administrations (for this reason, novel molecules with improved efficacy and reduced side effects are being developed) and by the possible ''leakiness'' (gene expression in the absence of the inducer) of the system. In one system, the small molecule drug is rapamycin, which mediates the formation of heterodimers between FKBP (FK506 binding protein) and FRAP (FKBPrapamycin associated protein). By fusing FKBP to a DNA binding domain (ZFHD1) and FRAP to a transcriptional activation domain (p65 from NF-jB), reconstitution of a functional transcription factor and expression of a target gene occur in the presence of rapamycin (Pollock et al., 2000; Rivera et al., 1996) . This system is entirely made of human components theoretically reducing the risk for immune responses in a gene therapy setting. It has been recently tested in the rodent and NHP retina (Auricchio et al., 2002) . Two AAV vectors, encoding the transcription factor (AAV2-CMVTF1nc) and the target gene (AAV2-Z12-rhEpo-2S6) respectively were produced. The gene encoding Erythropoietin (Epo), a soluble protein with functional activity and measurable with a commercial Elisa, was selected and a mixture of the two vectors was injected in the subretinal space of rats and NHP. Epo expression in the anterior chamber fluid was absent in the absence of the dimerizer rapamycin, and inducible in a dose dependent way upon administration. In addition, upon drug withdrawal, Epo levels in the ocular fluids dropped to levels similar to basal (Fig. 6) . Finally, recombinant Epo leaking from the ocular environment into the general circulation is minimal. Similar results were obtained by us and others ) using the tetracycline inducible system delivered to the retina via viral vectors.
Pharmacologically regulated systems therefore provide useful means to gain control over time and level of gene expression in the eye.
Conclusion
Proof of principal has recently been provided that gene delivery using AAV2 can restore vision in a large animal model of retinal disease. In addition, AAV vectors have been successfully tested in the eye of a number of rodent models and they are being evaluated in the NHP retina. Issues related to the safety of the vector, the evaluation of new serotypes potentially more appropriate to specific retinal applications and the regulation of gene delivery have not been completely solved. Nevertheless, the possibility to test AAV mediated therapies in humans affected with severe forms of retinal diseases seems close and appears now as a tangible option for the treatment of diseases otherwise inevitably leading to blindness.
